$28.47
▲ +0.1% Today
as of Sep 4, 16:53 ET
Last 30 days
Recent Press Releases & News
mixed
▲ 3
● 22
▼ 0
AbbVie vs. Pfizer: Which Healthcare Stock Is a Better Buy in 2026?
Pfizer’s Stock Has Been Crushed—Is Its 6% Dividend Finally Worth Buying?
Ionis’ rare neurology drug approved; Pfizer inks an ADC deal
Overview
52-week range
$24
$29
87% of range
Avg surprise (last 3)
+28.0%
Avg reaction (last 2)
+1.9%
100% positive
Latest IV / EM
31%
EM ±1.3% · $29 · Sep 4
Earnings trends
EPS — actual vs estimate
Actual Estimate
Revenue vs Net Income
Revenue Net income
Earnings history
| Date | Period | Actual EPS | Est | Surprise | YoY %Δ | Day react | Source |
|---|---|---|---|---|---|---|---|
| Sun Jun 28, 2026 | Jun 2026 | $-0.04 | — | — | — | — | financials |
| Tue May 5, 2026 | Mar/2026 | $0.75 | $0.71 | +5.6% | -18.5% | +0.6% | earnings |
| Sun Sep 28, 2025 | Sep 2025 | $0.62 | — | — | — | — | financials |
| Tue Aug 5, 2025 | Jun/2025 | $0.78 | $0.58 | +34.5% | — | — | earnings |
| Tue Apr 29, 2025 | Mar/2025 | $0.92 | $0.64 | +43.8% | — | +3.2% | earnings |
| Sun Sep 29, 2024 | Sep 2024 | $0.78 | — | — | — | — | financials |
| Sun Jun 30, 2024 | Jun 2024 | $0.01 | — | — | — | — | financials |
| Sun Mar 31, 2024 | Mar 2024 | $0.55 | — | — | — | — | financials |
| Sun Oct 1, 2023 | Oct 2023 | $-0.42 | — | — | — | — | financials |
| Sun Jul 2, 2023 | Jul 2023 | $0.41 | — | — | — | — | financials |
| Sun Apr 2, 2023 | Apr 2023 | $0.97 | — | — | — | — | financials |
Financials
Income statement (quarterly)
| Metric | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $15.03B | $14.45B | — | $16.65B | $14.65B | $13.71B | — | $17.70B |
| Cost of revenue | $4.09B | $3.55B | — | $4.17B | $3.78B | $2.85B | — | $5.26B |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | — | — | — | — | — | — | — | — |
| Net income | $-248M | $2.69B | — | $3.54B | $2.91B | $2.97B | — | $4.46B |
| EPS (diluted) | $-0.04 | $0.47 | — | $0.62 | $0.51 | $0.52 | — | $0.78 |
Balance sheet (quarterly)
| Metric | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $976M | $1.70B | $1.14B | $1.34B | $1.64B | $1.43B | $1.04B | $1.09B |
| Inventory | $9.95B | $10.67B | $10.65B | $11.47B | $11.67B | $10.85B | $10.85B | $11.72B |
| Total current assets | $41.36B | $42.82B | $42.90B | $46.92B | $43.70B | $45.86B | $50.36B | $43.22B |
| Total assets | $201.13B | $207.62B | $208.16B | $208.73B | $206.09B | $208.03B | $213.40B | $219.48B |
| Long-term debt | $60.49B | $60.56B | $61.64B | $57.41B | $57.50B | $57.64B | $57.41B | $58.00B |
| Total liabilities | $115.64B | $117.21B | $121.39B | $115.64B | $117.08B | $117.39B | $124.90B | $126.92B |
| Total equity | $85.19B | $90.40B | $86.48B | $92.80B | $89.01B | $90.64B | $88.20B | $92.56B |